Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). 

Biotechnology

Education

Liquidia

Roger Jeffs

Sarah Krepp

Jennifer Weidman

Jeff Kindig

Derek Schorzman

Scott Moomaw

Rajeev Saggar

Robert Lippe

Mike Kaseta

Rusty Schundler

Management

Sales and Marketing

Research and Development

Leadership Team

Accounting and Financial Operations

Medical Affairs Team